Breakthroughs in Cutting-Edge Therapies and Commercialization Challenges
1. Gene Editing Enters a New Era of "In Vivo Therapy"
In vivo gene editing therapies from companies like Intellia/Regeneron and Verve Therapeutics (targeting conditions such as ATTR amyloidosis and hypercholesterolemia) have released longer-term positive data, validating the safety and efficacy of the technology and offering hope for "one-time cures" for common diseases. Related therapies from domestic companies like Boya Jiyin have also entered Phase II clinical trials.
2. CAR-T Therapy: Intense Competition and Strategic Breakthroughs
CAR-T therapies for solid tumors have achieved sporadic but critical clinical breakthroughs (e.g., early data for gastric and pancreatic cancers), though a major breakthrough has yet to materialize. Competition in the hematological malignancy domain is intensifying, with dual-target CAR-T therapies (e.g., BCMA/CD19) and allogeneic CAR-T emerging as new focal points, and price wars are already beginning to surface in some markets.
3. ADC (Antibody-Drug Conjugates) Enters a "Platform Competition" Phase
Licensing and collaboration deals between multinational pharmaceutical companies like Pfizer, AstraZeneca, Merck & Co., GSK, and Chinese firms (e.g., Hengrui, Kelun, Yingen) remain active. However, target homogeneity is pronounced (e.g., TROP2, CLDN18.2, Nectin-4). Next-generation ADCs—such as dual-payload ADCs, bispecific ADCs, and immune-stimulating ADCs—are becoming the new frontier of value creation.
Recommended Posts
-
22-24th.April.2025 -
Xi'an Xinghui Material Technology Co., Ltd. is not just a workplace, but a 'home' where we grow together and achieve together. We firmly believe that every employee is the company's most valuable asset and the core force driving us forward. Here, we are committed to creating a professional, open, warm, and dynamic environment, allowing every family member to realize their value at work and feel cared for in life.
-
The EU's Key Medicines Act has entered the implementation phase, requiring the establishment of minimum inventories for key medicines and an increase in the local production ratio of active pharmaceutical ingredients (APIs). The United States continues to support domestic biomanufacturing through tools such as the Defense Production Act.
